Retatrutide has now been studied in thousands of people across Phase 2 and Phase 3 clinical trials.
That gives researchers a much clearer picture of its safety profile than was available when the first obesity results appeared in 2023.
The most consistent finding is not surprising: gastrointestinal side effects are the most common adverse events, particularly nausea, diarrhea, constipation, and vomiting.
But the expanding clinical program has also identified other signals worth understanding, including altered skin sensation, increases in heart rate in earlier trials, hypotension in some Phase 3 participants, and treatment discontinuation at higher doses.
Retatrutide remains investigational. It has not been approved by the FDA or any other regulatory agency, so its final prescribing information, contraindications, warnings, and long-term safety profile have not yet been established.
TL;DR
Across the retatrutide clinical program:
- Gastrointestinal adverse events are the most common.
- Nausea, diarrhea, constipation, and vomiting generally increase with dose.
- Many gastrointestinal events occur during dose escalation.
- Lower starting doses improved tolerability in Phase 2.
- Dysesthesia, or altered skin sensation, has appeared consistently in later trials.
- Phase 2 showed a temporary dose-related increase in heart rate.
- Phase 3 TRIUMPH-1 reported treatment discontinuation due to adverse events in roughly 4% to 11% of retatrutide participants, depending on dose.
- Serious adverse events have occurred, but the available trials have not identified a single dominant serious toxicity explaining the overall safety profile.
- Long-term cardiovascular, renal, and other safety outcomes are still under study.
What Counts as a Retatrutide Side Effect?
Clinical trials generally separate safety findings into several categories.
Adverse events are medical events occurring during a trial, regardless of whether investigators believe the study drug caused them.
Treatment-emergent adverse events are events that begin or worsen after treatment starts.
Serious adverse events meet specific criteria such as hospitalization, life-threatening events, major disability, or death.
Adverse events of special interest are events researchers watch closely because they may be relevant to the drug’s mechanism or drug class.
This distinction matters.
If a trial reports that 90% of participants experienced “an adverse event,” that does not mean 90% suffered a serious drug reaction.
Many trial adverse events are minor events such as nausea, diarrhea, respiratory infections, or headaches.
What Phase 2 First Showed
The 2023 Phase 2 obesity trial enrolled 338 adults and provided the first substantial picture of retatrutide tolerability.
Across the retatrutide groups, any treatment-period adverse event was reported in approximately 73% to 94% of participants, compared with 70% receiving placebo.
The most frequent problems were gastrointestinal.
These included:
- nausea
- diarrhea
- vomiting
- constipation.
The gastrointestinal events were generally:
- mild to moderate
- dose related
- concentrated around dose escalation.
An important observation was that starting at a lower dose reduced gastrointestinal side effects compared with beginning at a higher dose.
That finding influenced the way later retatrutide trials approached escalation.
Nausea Is One of the Most Common Retatrutide Adverse Events
The larger Phase 3 TRIUMPH-1 obesity study provides a clearer picture.
At 80 weeks, Lilly reported nausea in:
| Group | Nausea |
|---|---|
| Placebo | 14.8% |
| Retatrutide 4 mg | 28.6% |
| Retatrutide 9 mg | 38.4% |
| Retatrutide 12 mg | 42.4% |
The pattern is clearly dose related.
Nausea was therefore common at the higher retatrutide doses, although it was not universal.
Diarrhea, Constipation, and Vomiting
Other gastrointestinal events followed a similar pattern in TRIUMPH-1.
Diarrhea
- Placebo: 13.5%
- Retatrutide 4 mg: 25.2%
- Retatrutide 9 mg: 34.1%
- Retatrutide 12 mg: 32.0%
Constipation
- Placebo: 10.9%
- 4 mg: 23.8%
- 9 mg: 25.9%
- 12 mg: 26.1%
Vomiting
- Placebo: 4.8%
- 4 mg: 10.6%
- 9 mg: 22.8%
- 12 mg: 25.3%
Taken together, these results make gastrointestinal tolerability one of the clearest dose-related tradeoffs in retatrutide research.
Phase 3 Diabetes Data Showed the Same General Pattern
The first fully peer-reviewed Phase 3 retatrutide trial was TRANSCEND-T2D-1.
The study enrolled 537 adults with type 2 diabetes and was published in The Lancet in June 2026.
The most frequent adverse events were again gastrointestinal and generally mild to moderate.
Reported nausea occurred in:
- 16.4% with 4 mg
- 19.5% with 9 mg
- 26.5% with 12 mg
- 3.7% with placebo.
Diarrhea occurred in:
- 18.7%
- 26.3%
- 22.8%
- 4.5% with placebo.
Vomiting occurred in:
- 15.7%
- 15.0%
- 17.6%
- 2.2% with placebo.
The exact rates differed from the obesity trial, but the overall signal was consistent.
Gastrointestinal effects remain the most common tolerability issue.
What Is Dysesthesia?
One of the more distinctive safety findings with retatrutide is dysesthesia.
Dysesthesia refers to an abnormal or altered sensation.
People may describe sensory changes as:
- tingling
- burning
- increased sensitivity
- uncomfortable skin sensation
- altered touch sensation.
In the original Phase 2 obesity trial, cutaneous hyperesthesia and related skin-sensitivity events occurred in around 7% of retatrutide participants versus about 1% receiving placebo.
The reported events were not severe or serious and did not cause treatment discontinuation.
The signal persisted into Phase 3.
In TRIUMPH-1, dysesthesia occurred in:
- 5.1% with 4 mg
- 12.3% with 9 mg
- 12.5% with 12 mg
- 0.9% with placebo.
In TRANSCEND-T2D-1, rates were lower:
- 4.5% with 4 mg
- 2.3% with 9 mg
- 4.4% with 12 mg
- 0% with placebo.
The reason for the difference between studies is not yet clear.
Lilly has reported that these events were generally mild to moderate and that most resolved while participants remained on treatment.
Heart Rate Increased in Phase 2
Retatrutide’s glucagon and GLP-1 receptor activity makes cardiovascular monitoring particularly interesting.
In the Phase 2 obesity trial, heart rate increased in a dose-dependent manner.
The increase peaked around week 24 and then declined at weeks 36 and 48.
Investigators noted that the magnitude was similar to increases reported with GLP-1 receptor agonists.
This was not presented as evidence of a proven cardiovascular hazard.
But it is one reason longer cardiovascular-outcome studies matter.
What About Arrhythmias?
The Phase 2 obesity trial reported cardiac arrhythmia-related adverse events in approximately 6% of retatrutide participants overall.
Most were mild or moderate.
One severe event involving prolonged QT occurred in a participant also treated with ondansetron.
Small numbers like these should be interpreted carefully.
They can identify a signal worth monitoring without proving that the investigational drug caused the event.
Hypotension Has Appeared in Phase 3
TRIUMPH-1 also identified reported hypotension as an adverse event of special interest.
The ADA presentation noted that hypotension was more common among participants taking antihypertensive medications.
This makes biological sense in a study where blood pressure itself was decreasing substantially.
But the exact relationship between weight reduction, medications, hydration, and retatrutide’s direct effects requires careful interpretation.
Serious Adverse Events
Serious adverse events are important because they distinguish everyday tolerability problems from medically significant events.
In the Phase 2 obesity trial, serious adverse events occurred in about 4% of participants in both the retatrutide and placebo groups.
TRIUMPH-1 involved a much larger and longer Phase 3 population.
The ADA presentation reported serious adverse events in:
- 5.5% of placebo participants
- approximately 7.7% to 10.5% of retatrutide participants.
Those figures do not mean every serious event was caused by retatrutide.
Trials record serious medical events regardless of causality and then investigate their relationship to treatment.
Pancreatitis and Pancreatic Enzymes
The Phase 2 obesity study reported increases in amylase and lipase levels.
Most were asymptomatic.
There was also one serious adverse event of acute pancreatitis.
A single case cannot establish a precise risk rate.
Pancreatic safety remains an area monitored across incretin-based drug development.
Gallbladder and Biliary Events
Biliary events also appeared in the Phase 2 obesity trial.
Three participants receiving retatrutide experienced biliary disorders, including cases of cholelithiasis and cholecystitis.
Rapid or substantial weight loss itself is associated with changes in gallstone risk, making it difficult to separate treatment mechanism from effects associated with weight reduction.
Larger studies are needed to estimate uncommon-event rates more reliably.
Hypoglycemia
Retatrutide affects glucose regulation, so hypoglycemia is another important question.
The Phase 2 obesity trial did not report clinically significant level 2 or level 3 hypoglycemia.
The Phase 3 TRANSCEND-T2D-1 trial likewise reported no severe hypoglycemia.
That study evaluated retatrutide as monotherapy in people whose diabetes was being managed with diet and exercise, which is important context when interpreting the result.
Hypoglycemia risk could differ when glucose-lowering drugs are combined.
Treatment Discontinuation Tells Us About Tolerability
Another useful safety measure is how often participants stop treatment because of adverse events.
In Phase 2 obesity research, adverse-event discontinuation occurred in approximately 6% to 16% of participants receiving retatrutide, depending on the group.
Phase 3 dosing strategies appear to have improved tolerability in some populations.
In TRIUMPH-1:
- 4.1% discontinued because of adverse events at 4 mg
- 6.9% at 9 mg
- 11.3% at 12 mg
- 4.9% with placebo.
Gastrointestinal adverse events were the most common reason for discontinuation.
The pattern shows an important point about retatrutide research:
greater pharmacological effect does not necessarily mean greater practical tolerability.
The highest studied doses generally produce greater weight reduction but also more adverse events.
Phase 3 Results Continue to Expand the Safety Database
In July 2026, Lilly reported topline results from TRIUMPH-2 and TRIUMPH-3.
Both again showed gastrointestinal events as the dominant side effects.
TRIUMPH-2 included adults with obesity or overweight and type 2 diabetes. TRIUMPH-3 included adults with severe obesity and established cardiovascular disease.
Dysesthesia continued to appear.
Discontinuation due to adverse events ranged from:
- 3.8% to 11.6% across TRIUMPH-2 retatrutide groups
- 9.8% to 13.5% in TRIUMPH-3 retatrutide groups.
These results broaden the safety database, but detailed peer-reviewed publications from these trials are still important.
Topline company announcements do not provide the same depth of information as full peer-reviewed trial reports.
Why Evidence Status Matters
Not all current retatrutide safety data have the same evidentiary status.
As of September 2026:
Peer reviewed
- Phase 2 obesity trial
- Phase 2 type 2 diabetes trial
- body-composition substudy
- TRANSCEND-T2D-1 Phase 3 trial
Presented or company reported
- detailed TRIUMPH-1 Phase 3 results presented at ADA 2026
- TRIUMPH-2 topline results
- TRIUMPH-3 topline results.
This does not mean the company-reported findings are unreliable.
It means researchers have less access to complete methodology, subgroup data, event adjudication, and supplementary analyses until the full papers are published.
Long-Term Safety Is Still an Open Question
Phase 3 trials provide much stronger safety information than early trials.
But some questions require even longer observation.
These include:
- cardiovascular outcomes
- kidney outcomes
- uncommon adverse events
- long-term gallbladder effects
- long-term pancreatic safety
- consequences of maintaining very large weight reductions
- effects on muscle and bone
- safety in older or frail populations.
The ongoing TRIUMPH-Outcomes trial is specifically evaluating cardiovascular and kidney outcomes in adults with obesity.
Those studies are important because a drug intended for chronic treatment needs evidence extending beyond short-term weight reduction.
Is Retatrutide Safe?
It is too early to give retatrutide the kind of definitive safety statement that can be made for an established approved medication.
The scientific evidence currently supports a narrower conclusion:
Retatrutide has produced a generally recognizable incretin-like safety profile in clinical trials, dominated by gastrointestinal adverse events, while additional signals including dysesthesia, heart-rate changes, hypotension, and uncommon serious events continue to be evaluated.
The safety database is now much larger than it was after Phase 2.
But retatrutide remains investigational.
There is no FDA-approved retatrutide product, no finalized prescribing information, and no established clinical safety profile for use outside controlled trials.
That distinction is particularly important when interpreting products sold online under the retatrutide name. Clinical-trial safety data apply to the investigational material studied under Lilly-sponsored protocols and should not automatically be generalized to unregulated products of unknown identity, purity, concentration, or composition.
References
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023. Read the NEJM study
Bajaj HS, et al. Efficacy and safety of retatrutide in people with type 2 diabetes: TRANSCEND-T2D-1. The Lancet. 2026. PubMed
Eli Lilly and Company. TRIUMPH-1 Phase 3 results. TRIUMPH-1 ADA presentation
Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 topline results. July 2026. Lilly Phase 3 announcement
Eli Lilly and Company. What to Know About Retatrutide. Lilly retatrutide information